Marina Demidiuk
Cases of monkeypox in the US have been on a steady decline since peaking in August, CDC data shows.
As of Oct. 26, the 7-day moving average of daily cases was 30. That’s down from a 7-day moving average peak of 446 on August 7.
As of Oct. 26, HHS’ Administration for Strategic Preparedness and Response (OTC:ASPR) has shipped ~851.3K vials of Bavarian Nordic’s (OTCPK:BVNKF)(OTCPK:BVNRY) Jynneos vaccine to states. The CDC reports just over 1M doses have been administered (The discrepancy is because the shot has been given intradermally since August, using one-fifth of the amount that would be used if given subcutaneously, to stretch out supply.).
ASPR has previously stated it will make 1.1M vials available.
After hitting a 52-week high of $58.02 on Aug. 4, Bavarian Nordic (OTCPK:BVNRY) shares are down 48% since then.
SIGA Technologies, the maker of TPOXX, a smallpox therapy that can be used to treat monkeypox, is also down ~66% since its 52-week high of $26.96 on Aug 15.
Read Seeking Alpha contributor Clinically Sound Investor’s argument for why SIGA (SIGA) and monkeypox have both peaked.